Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bludigo in Pediatric Patients for Ureteral Patency
NCT06448143Phase 3Not yet recruiting
- Sponsor
- Provepharma
- Start
- Dec 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of indigotindisulfonate sodium in ureter injury, sponsored by Provepharma. Primary endpoint: Responders to Bludigo at 10 minutes. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
indigotindisulfonate sodium
03
Conditions
ureter injury
Beyond the preview
Go deeper on NCT06448143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448143.